HOPO THERAPEUTICS, INC.

Hopo Therapeutics, Inc. specializes in the research and development of novel medical countermeasures for internal contamination by radionuclides and toxic heavy metals, with a focus on decorporation agent design and preclinical evaluation. Their technical expertise lies in pharmacokinetic optimization, radiopharmaceutical chemistry, and targeted chelation therapy development, grounded in life sciences research methodologies compliant with federal biomedical standards. The company’s key differentiator is its precision approach to molecular design for enhanced metal binding affinity and reduced off-target toxicity, positioning them at the intersection of medicinal chemistry and public health preparedness. Their work directly supports national defense and emergency response frameworks by advancing agents intended for use in radiological or nuclear incident scenarios. Hopo Therapeutics has demonstrated direct engagement with the Department of Health and Human Services, primarily advancing biomedical countermeasure development under programs aligned with the Biomedical Advanced Research and Development Authority (BARDA) and the Strategic National Stockpile. Their relationship with HHS is centered on translational research aimed at transitioning laboratory-stage compounds into viable medical countermeasures, reflecting a focused partnership in public health emergency preparedness. The contractor operates primarily under NAICS 541715, which encompasses applied research in life sciences with an emphasis on therapeutic discovery and non-biotech pharmaceutical development. This places them squarely within the biomedical countermeasures and radiological health market, serving federal agencies requiring novel therapeutics for mass casualty scenarios. Their market positioning is niche but mission-critical, targeting high-priority gaps in nuclear and heavy metal decontamination. Hopo Therapeutics, Inc. is a small business structured as a 2L entity, headquartered in Berkeley, California. While no federal certifications are currently listed, their work is conducted under rigorous scientific and regulatory frameworks aligned with FDA and HHS guidelines for medical countermeasure development. Their geographic base in the Bay Area provides access to leading academic and biotech ecosystems, reinforcing their capacity for innovation in advanced therapeutic development.